Enlivex Therapeutics Ltd.
A clinical-stage macrophage reprogramming immunotherapy company.
ENLV | TA
Overview
Corporate Details
- ISIN(s):
- IL0011319527
- LEI:
- Country:
- Israel
- Address:
- Weizmann Science Park, 14 Einstein St., 7403618 Ness Ziona
- Website:
- https://enlivex.com/
- Sector:
- Manufacturing
Description
Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-19 08:55 |
Immediate Report of Meeting
|
English | 147.4 KB | ||
| 2025-12-19 08:55 |
Immediate Report of Meeting
|
English | 351.9 KB | ||
| 2025-12-19 08:55 |
Immediate Report of Meeting
|
English | 100.4 KB | ||
| 2025-12-04 16:11 |
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token S…
|
English | 147.9 KB | ||
| 2025-12-04 16:11 |
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token S…
|
English | 36.3 KB | ||
| 2025-11-26 16:14 |
Immediate Report
|
English | 198.6 KB | ||
| 2025-11-26 16:14 |
Immediate Report
|
English | 36.3 KB | ||
| 2025-11-24 17:15 |
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Pred…
|
English | 9.9 MB | ||
| 2025-11-24 17:15 |
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Pred…
|
English | 36.4 KB | ||
| 2025-11-24 17:12 |
Renewal of shelf prospects effective of May 12, 2025
|
English | 506.3 KB | ||
| 2025-11-24 17:12 |
Renewal of shelf prospects effective of May 12, 2025
|
English | 36.4 KB | ||
| 2025-11-24 16:30 |
The company's announcement regarding $212,000,000 Private Placement was publish…
|
English | 62.4 KB | ||
| 2025-11-24 15:44 |
Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduct…
|
English | 4.4 MB | ||
| 2025-11-24 15:44 |
Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduct…
|
English | 36.4 KB | ||
| 2025-11-18 16:14 |
Results of a meeting held on November 7, 2025
|
English | 127.9 KB |
Automate Your Workflow. Get a real-time feed of all Enlivex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Enlivex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Enlivex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
